Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-06954522 IR (Formulation 1)
PF-06954522 IR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 1 , Formulation 2, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 2 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 2, Formulation 3, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 3 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 3, Formulation 1, and Formulation 2, under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 4 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 3, Formulation 2, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 5 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 1, Formulation 3, and Formulation 2 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 6 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 2, Formulation 1, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively. |
| Name | Type | Description |
|---|---|---|
| PF-06954522 IR (Formulation 1) | DRUG | Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth |
| PF-06954522 MR (Formulation 2) | DRUG | Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth. |
| PF-06954522 MR (Formulation 3) | DRUG | Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth |
Inclusion Criteria: * Male and female participants of non-childbearing potential aged 18 years or older who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and electrocardiograms. * Body mass index of 16-32 kg/m...
PF-06954522 IR is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is an immediate-release formulation of PF-06954522 that has been studied in healthy adult volunteers. The therapeutic indication for PF-06954522 IR has not been disclosed.
PF-06954522 IR is made by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the developer of the compound and sponsored the clinical study evaluating this immediate-release formulation in healthy adult participants.
PF-06954522 IR is in Phase 1 clinical development. It is an investigational drug and is not approved by the FDA. One Phase 1 trial of PF-06954522 IR has been completed, and no trials of this formulation are currently active.
PF-06954522 IR has been evaluated in one completed Phase 1 trial, NCT06393517, titled a study to learn how different forms of the study medicine called PF-06954522 are taken up into the blood in healthy adults. The trial enrolled 23 healthy participants in the United States and was controlled and randomized.
PF-06954522 IR is also known as PF-06954522 IR (Formulation 1). It is an immediate-release formulation of the study medicine PF-06954522, so searches for either name refer to the same investigational compound being developed by Pfizer.